Effects of enzymatically modified isoquercitrin in supplementary protein powder on athlete body composition: a randomized, placebo-controlled, double-blind trial by 麻見 直美 et al.
Effects of enzymatically modified
isoquercitrin in supplementary protein powder
on athlete body composition: a randomized,
placebo-controlled, double-blind trial
著者（英） Naomi OMI, Hideki Shiba, Eisaku Nishimura,
Sakuka Tsukamoto, Hiroko Maruki-Uchida, Masaya
Oda, Minoru Morita
journal or
publication title
Journal of the International Society of Sports
Nu rition
volume 16
number 1
page range 39
year 2019-09
権利 (C) The Author(s). 2019 Open Access This
article is distributed under the terms of the
Creative Commons Attribution 4.0 International
License
(http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution,
and reproduction in any medium, provided you
give appropriate credit to the original
author(s) and the source, provide a link to
the Creative Commons license, and indicate if
changes were made. The Creative Commons Public
Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/
1.0/) applies to the data made available in
this article, unless otherwise stated.
URL http://hdl.handle.net/2241/00159540
doi: 10.1186/s12970-019-0303-x
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
RESEARCH ARTICLE Open Access
Effects of enzymatically modified
isoquercitrin in supplementary protein
powder on athlete body composition: a
randomized, placebo-controlled, double-
blind trial
Naomi Omi1,2*, Hideki Shiba2, Eisaku Nishimura3, Sakuka Tsukamoto3, Hiroko Maruki-Uchida3, Masaya Oda2 and
Minoru Morita3
Abstract
Background: Enzymatically modified isoquercitrin (EMIQ), a water-soluble quercetin, has been shown to intensify
muscle hypertrophy in mice. We investigated the effect of EMIQ in supplementary protein powder on athlete body
composition.
Methods: Forty Japanese males who played American football (age: 19.8 ± 1.4 years; body height: 174.1 ± 6.0 cm;
body mass: 75.5 ± 10.7 kg) were assigned to a randomized, placebo-controlled, double-blind trial of parallel
group. Participants received either EMIQ in whey protein (EW, n = 19) or contrast whey protein (W, n = 20) 6
days per week over 4 months. Body composition was assessed using dual-energy X-ray absorptiometry.
Markers of oxidative stress, derivatives of reactive oxygen metabolites (d-ROMs) and biological antioxidant
potential (BAP), were assessed using a free radical analytical system. Data were analyzed using a univariate
and repeated measures general model statistics.
Results: After 4 months, changes in lower limb fat-free mass and muscle mass were significantly greater in
the EW group than in the W group (mean change ±95% CI; W: 324.1 ± 284.3, EW: 950.3 ± 473.2, p = 0.031, W:
255.7 ± 288.6, EW: 930.9 ± 471.5, p = 0.021, respectively). Moreover, the EW group exhibited a significantly
higher BAP/d-ROMs ratio, antioxidation index, than the W group after 4 months (mean change ± SD; W: 8.8 ±
1.1, EW: 10.3 ± 2.8; p = 0.028). No significant differences in body mass, lean body mass, fat mass, or lower limb
fat mass were observed between the groups.
Conclusion: Ingestion of EMIQ in supplementary protein powder for 4 months exerts antioxidant effects and
increases muscle mass among American football players.
Trial registration: University Hospital Medical Information Network Clinical Trial Registry, UMIN000036036.
Retrospectively registered in 2019.
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Background
Rutin is a polyphenolic flavonoid compound found in
many plants (e.g., citrus fruits, onions, and buckwheat)
and exhibits strong antioxidant effects [1]. Rutin has
vitamin-like and medicine-like effects, including prevent-
ing cardiovascular and metabolic diseases [2]. However,
it is difficult for humans to absorb rutin [3]; therefore, it
is converted to quercetin and its metabolites prior to
absorption.
Enzymatically modified isoquercitrin (EMIQ), enzymati-
cally modified rutin, and α-glycosyl isoquercitrin are glu-
cosyl derivatives of quercetin. EMIQ is manufactured
from rutin through enzymatic modification. The enzym-
atic treatment increases the water solubility of EMIQ; the
bioavailability of EMIQ is approximately 17 times that of
quercetin and 45 times that of rutin [4]. Compared to
rutin, EMIQ is also more easily absorbed in humans [5].
Therefore, EMIQ is expected to provide greater health
benefits than quercetin and rutin. EMIQ is approved as a
safe food additive and an antioxidant [6, 7].
Mukai et al. reported that quercetin has a preventive
effect on muscle atrophy [8]. They have reported that
quercetin injection in rats suppressed the reduction of
muscle mass by attenuating the induction of ubiquitin
ligase. They also found that quercetin prevented muscle
atrophy by targeting mitochondrial function [9]. Lee-
layuwat et al. reported that quercetin administration in-
creased the cross-sectional area of skeletal muscles in
swimming rats and promoted recovery from muscle in-
flammation after severe exercise [10]. Moreover, we
found that EMIQ, a water-soluble quercetin, intensified
muscle hypertrophy in mice [11]. Therefore, we hypoth-
esized that supplementation with EMIQ will produce
positive changes in human muscles as well.
Oxidative stress is closely related to exercise. Moderate
exercise increases oxidative stress, prompting muscle
hypertrophy [12]; whereas intense and prolonged exer-
cise causes high levels of reactive oxygen species,
prompting muscle weakness and fatigue [13, 14]. Deriva-
tives of reactive oxygen metabolites (d-ROMs) and bio-
logical antioxidant potential (BAP) were used as
oxidative stress markers in a clinical study [15]. d-ROMs
indicate oxidative stress in blood samples; BAP indicates
antioxidant ability, and the BAP/d-ROMs ratio repre-
sents the antioxidation index. A previous study reported
that BAP/d-ROMs ratio was positively correlated with
performance increase [16]; however the effects of antiox-
idants on muscle mass are not well understood.
Muscle protein constantly undergoes synthesis and
breakdown, and skeletal muscle mass is regulated by
many signals [17], including exercise, physical tension,
nutrients, hormones, and cytokines [18]. Increased pro-
tein synthesis rather than the breakdown of muscle pro-
tein, causes increase muscle mass [19]. After exercising
in the fasting state, the net muscle protein balance be-
comes negative, whereas when protein is ingested after
the exercise, the net muscle protein balance becomes
positive [20]. Therefore, many athletes use supplemen-
tary protein powder to gain skeletal muscle mass [21,
22].
In the present study, we examined the effects of the
consumption of EMIQ on body composition and anti-
oxidant status of American football players who undergo
strong exercise training regularly. They typically con-
sume supplementary protein powder, and EMIQ is sup-
plied with protein powder. We hypothesized that EMIQ
treatment will significantly increase lean mass and lower
limb muscle mass. We further hypothesized that EMIQ
treatment will significantly affect the antioxidant status.
Methods
Study design and participants
This randomized, parallel arm, placebo-controlled,
double-blind study was conducted for 4 months in 2014.
Primary outcomes were changes in lean mass and lower
limb muscle mass, and secondary outcomes were
changes in the antioxidant status. The study’s protocol
was approved by the Ethics Committee of Tsukuba Uni-
versity (2014.7.30, no. 26–37), and the study was per-
formed in accordance with the guidelines of the
Declaration of Helsinki Declaration and the 2010 Con-
solidated Standards of Reporting Trials statement [23].
The trial was retrospectively registered in the University
Hospital Medical Information Network Clinical Trial
Registry (Japan, registration no. UMIN000036036) in
2019. Forty male Japanese students (from the Tsukuba
University) who played American football (BMI ≥18.5
and < 30) were recruited to participate in the study. All
participants provided written informed consent and were
assigned to receive either EMIQ in whey protein (the
EW group) or contrast whey protein (the W group), and
the groups were stratified according to grade (junior vs.
senior) and football position (back vs. lineman) using the
“rand” function of Microsoft Excel (version 14.4.7). Time
limits of whey protein powder with/without EMIQ are
18months, and the protein was consumed within this
limit. During the study period, the groups were identi-
fied as group A (the W group) and group B (the EW
group) to ensure blinding.
Exclusion criteria
The following participants were excluded:
1) Participants with food allergies.
2) Participants who consume other supplementary
protein powders, drugs, or supplements during the
study.
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3) Participants who change their lifestyle, including
dietary and exercise habits, during the study.
4) Participants who eat unbalanced diet (consuming
much polyphenol-rich food, including citrus fruit,
buckwheat, and fermented soybeans), or consume
excessive alcohol.
5) Participants who refrained from practice for long
periods (e.g., because of injury).
One of the recruited participants was excluded because
he failed to provide a blood sample.
Characteristics of participants and training program
Most participants had previously consumed supplemen-
tary protein powder (typically whey protein, 3–4 times a
week after resistance training). The study’s flow chart
and assessment schedule are shown in Figs. 1 and 2,
respectively.
The football team’s trainer provided input regarding
the design of the training program. Resistance training
to maintain or increase skeletal muscle mass and power
was performed 3 times a week during the first month
(from 0month to 1 month). Participants also underwent
skill training to increase their individual performance
and teamwork. From 1month to 2 month, the partici-
pants underwent moderately intense training (to develop
physical strength and complete a training camp). From
2month to 4month, practice sessions/games were con-
ducted 5–6 times a week (the competitive season).
Supplementation protocols
Participants consumed 20 g per day of whey supplemen-
tary protein powder (the W group) or 20 g of whey sup-
plementary protein powder with 42 mg of EMIQ (the
EW group). As calculated, participants consumed 0.26 g/
kg whey protein powder, and which indicates 0.18 g/kg
protein. Consumption amount of protein was deter-
mined on the basis of previous participants’ habits and
previous reports [24, 25]. All supplements were con-
sumed 6 times a week (immediately after practice).
Fig. 1 Study flow chart. Forty young male Japanese university students who played American football were recruited, although one participant
was excluded because he did not provide blood sample. Thus, 39 participants were randomized to receive either whey protein (W) or EMIQ in
whey protein (EW)
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Nutritional components of the supplements are shown
in Tables 1 and 2. Moisture and mineral contents were
0.8 g and 0.5–0.96 g, respectively.
EMIQ in the supplements was analyzed using a pre-
viously described high-performance liquid chromatog-
raphy method [26] that revealed that the whey protein
powder contained 0.0 mg of EMIQ and whey protein
powder with EMIQ contained 42 mg of EMIQ. All
supplements were prepared by Morinaga & Co. Ltd.
(Tokyo, Japan).
Body composition measurements
Body weights were measured using a body composition
meter (MC-190; TANITA, Japan) at baseline and 4
months. Body composition parameters (bone mineral
content, fat mass, and muscle mass) were measured
using dual-energy X-ray absorptiometry (DXA; QDR-
4500A; Hologic, Japan) at baseline and 4months. DXA
measurements were conducted following overnight fast
and 24-h absence of strenuous exercise. Participants
wore typical athletic clothing and removed all metal
jewelry. Participants were laid on their back on the DXA
table with their arms at their sides and feet together.
The same investigator conducted all analyses, and the
second measurement was performed as a comparable
mode. The investigator checked the setting of analysis
region. Lower limb were separated from the trunk by a
horizontal line just below the lower pelvic. Analysis pro-
vided data on lean body mass, fat mass, and bone
mineral content for the total body and lower limb.
Lower limb fat-free mass was calculated from lower limb
lean mass plus lower limb bone mineral content. Lower
limb lean mass was expressed as lower limb muscle mass
because lower limbs consist mostly of skeletal muscle,
bone, and fat [27].
Nutritional evaluations
To assess food intake, participants completed food fre-
quency questionnaires (FFQg version 3.5; Kenpaku-sha,
Tokyo, Japan) at baseline, 2 months, and 4 months (on
the same day as their body weight measurements). Sup-
plementation with protein powder for this study was not
included in these nutritional evaluations.
Fig. 2 Study protocol. Participants consumed 20 g of their supplementary protein powder after exercise (6 days a week). Body composition was
measured using dual-energy X-ray absorptiometry (DXA) at 0 and 4months. Weight measurements and nutritional evaluations were performed at
0, 2, and 4 months. Medical check-ups were performed with blood sampling at 0 and 4months. Oxidative stress was measured at 0 and 4
months. B: body composition measurement, W: weight measurement, N: nutritional evaluation, M: medical check-up, O: oxidative
stress measurement
Table 1 Nutrition facts per 20 g supplementation
Per 20 g supplementation
W EW
Energy 76 kcal
Protein 13.3 g.
Fat 0.14~0.60 g
Carbohydrate 4.8 g
EMIQ – 42 mg
Table 2 Amino acid composition
(g/100 g supplement)
Ala 3.44
Arg 1.49
Asp 7.47
Cys 3.2
Glu 12.4
Gly 1.17
His 1.24
Ile 4.26
Leu 7.12
Lys 6.24
Met 1.36
Phe 2.14
Pro 4.27
Ser 3.29
Thr 4.75
Typ 1.2
Tyr 1.91
Val 3.92
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Blood sampling
Blood sampling was performed at baseline and 4months.
The venous blood samples were collected in vacutainers in
the morning after overnight fasting and 24-h absence of
strenuous exercise; 2mL was drawn for general testing and
9mL for liver and renal function testing. All blood samples
were analyzed at the Tsukuba i-Laboratory. The blood test
parameters were red blood cell (RBC), and white blood cell
(WBC) counts, hemoglobin (Hb), hematocrit (Ht), mean
corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), mean corpuscular hemoglobin concentration
(MCHC), total bilirubin (T-BIL), creatinine (Crea), uric acid
(UA), urea nitrogen (UN), aspartate transaminase (AST),
alanine transaminase (ALT), lactate dehydrogenase (LDH),
platelet (PLT), and γ-glutamyl transpeptidase (γ-GTP).
RBC and WBC were measured using the electric resistance
method. Hb was measured using the sodium lauryl sulfate-
Hb method. Ht was measured using the RBC pulse peak
method. MCV was calculated as follows: Ht(%)/RBC (106/
mm3) × 10. MCHC was calculated as follows: Hb(g/dL)/Ht
(%) × 100. T-BIL, Crea, and UA were measured using the
enzymatic method. UN was measured the urease-UV
method. AST, ALT, LDH, PLT, and γ-GTP were measured
the Japan Society of Clinical Chemistry standardization
method.
Oxidative stress analysis
Blood samples were collected from participants’ finger-
tips in the morning after overnight fasting and 24-h ab-
sence of strenuous exercise at 0 and 4months. The d-
ROMs were measured using a free radical system
(FRAS4; Health & Diagnostics Ltd., Italy) and measure-
ment kits (DIACRON, Italy). The d-ROMs results were
expressed in arbitrary units, with one unit corresponding
to 0.08 mg/dL of hydrogen peroxide. BAP was also mea-
sured using the FRAS4 system and DIACRON measure-
ment kits. The BAP results were expressed in mmol/L of
reduced ferric ions.
Statistical analysis
Data were expressed as mean ± standard deviation, and
changed data were expressed as mean change ±95% CI.
Data were analyzed using a general linear model (GLM)
with repeated measures two-way analysis of variances
(ANOVA), with two levels by time (pre- and post-test or
pre-, 2 months, and post-test) and groups (W and EW)
as the Levene’s test revealed homoscedasticity and the
Kolmogorov-Smirnov test revealed normality. In some
cases, simple main effect test was performed following
repeated measures two-way ANOVA. Changed data
were analyzed using a GLM with one-way ANOVA as
the Levene’s test revealed homoscedasticity and the Kol-
mogorov-Smirnov test revealed normality. In addition,
effect size (ES) was calculated with Cohen’s d as a
standardized measurement based on SD differences.
Values closer to 1 is indicated substantive signifi-
cance. Statistical analyses were performed using the
SPSS software (version 22.0; SPSS Inc., Chicago, IL,
USA), and differences were considered statistically
significant at p < 0.05.
Results
Nutrient intake
The FFQg questionnaire was used to evaluate nutrient
intake; supplementary protein intake was not included
in this questionnaire. There were no significant differ-
ences in nutrient intake differences during the study pe-
riods. There were no significant differences in nutrient
intake during between the W and EW groups at 4
months, suggesting that dietary habits had no effect on
the results (Table 2).
Blood test results
Results of blood tests at baseline and 4months are
shown in Table 3. One of the participants in the W
group and three of those in the EW group could not
provide blood samples at baseline because of not meet-
ing the schedules. Only AST values were higher in the
W group than in the EW group during the experiment.
There was no significant changes due to EMIQ supple-
mentation. RBC, and WBC counts, Hb, Ht, MCV, Crea,
ALT, PLT, and γ-GTP increased from baseline to 4
months, possibly because of the strenuous training.
However, the participants exhibited no significant devia-
tions from the reference ranges for blood parameters
during the study period. No adverse events were associ-
ated with the investigational product during the study
period.
Body composition results
Basic information of the two groups is shown in Table 4,
and body composition data at baseline and 4months are
shown in Table 5. There were no differences in the basic
information between the two groups. Lower limb fat-free
mass, lower limb muscle mass, and lower limb fat mass
increased from baseline to 4 months, possibly because of
the strenuous training and protein consumption. In-
crease in lower limb fat-free mass and lower limb muscle
mass was markedly observed in the EW group (Group ×
Time interaction). Changes in the body composition
from baseline to 4 months are shown in Fig. 3. Increases
in lower limb fat-free and muscle masses were signifi-
cantly greater in the EW group than in the W group
(p = 0.030, and 0.020, respectively), with a large effect
size (SE = 0.740, and 0.800, respectively). There were no
significant differences in changes in lean body mass, fat
mass and lower limb fat mass between the groups.
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Antioxidant measurements
Antioxidant measurements are shown in Table 6. The
EW and W groups did not exhibit any significant
differences in BAP and d-ROMs at baseline. From
baseline to 4 months, d-ROMs increased, indicating
that the strenuous training increased plasma d-ROMs.
Group interaction of BAP/d-ROMs showed 0.075;
therefore, we analyzed simple main effect of groups.
BAP/d-ROMs ratio at 4 months was significantly
higher in the EW group than in the W group (p = 0.028,
and ES = 0.750) Table 7.
Discussion
The present study revealed that 4-month EMIQ supple-
mentation in whey protein powder significantly in-
creased lower limb lean mass in American football
players. The EMIQ group also exhibited higher BAP/d-
ROMs ratio than the control group after 4 months,
Table 3 Nutrient intakes
W group (n = 20) EW group (n = 19) interaction p value
Energy Baseline 38 ± 15 43 ± 16 Group 0.168
(kcal/kg BW) 2 months 36 ± 14 41 ± 13 Time 0.065
4 months 35 ± 10 38 ± 14 Group×Time 0.892
Protein Baseline 1.1 ± 0.4 1.3 ± 0.5 Group 0.263
(g/kg BW) 2 months 1.1 ± 0.4 1.2 ± 0.4 Time 0.156
4 months 1.1 ± 0.4 1.2 ± 0.4 Group×Time 0.681
Fat Baseline 1.1 ± 0.4 1.3 ± 0.5 Group 0.273
(g/kg BW) 2 months 1.1 ± 0.4 1.2 ± 0.4 Time 0.075
4 months 1.1 ± 0.4 1.2 ± 0.5 Group×Time 0.729
Carbohydrate Baseline 5.7 ± 2.5 6.2 ± 2.5 Group 0.375
(g/kg BW) 2 months 5.3 ± 2.2 6.0 ± 2.2 Time 0.101
4 months 5.1 ± 1.5 5.5 ± 2.1 Group×Time 0.874
Data are mean ± SD; BW body weight
Table 4 Blood test results
W group (n = 20) EW group (n = 19) Interaction p value
Baseline 4 months Baseline 4 months Group Time Group×Tim
RBC (× 105/μL) 5.0 ± 0.3 5.3 ± 0.3 5.0 ± 0.3 5.3 ± 0.4 0.311 0.003 0.260
WBC (× 1000/μL) 6.9 ± 1.2 7.7 ± 1.8 6.2 ± 1.1 7.1 ± 1.3 0.218 0.001 0.641
Hb (g/dL) 15.4 ± 0.8 15.6 ± 0.6 15.6 ± 0.8 15.9 ± 0.9 0.477 0.016 0.244
Ht (%) 44.2 ± 2.1 46.2 ± 1.7 44.8 ± 2.2 46.7 ± 2.7 0.441 0.003 0.253
MCV (fL) 87.5 ± 2.5 87.6 ± 2.2 88.9 ± 3.0 88.9 ± 2.5 0.433 0.040 0.275
MCH (pg) 30.4 ± 1.2 29.6 ± 1.1 30.9 ± 0.9 30.2 ± 0.9 0.472 0.119 0.266
MCHC (%) 34.8 ± 0.6 33.8 ± 0.7 30.9 ± 10.7 34.0 ± 0.7 0.308 0.124 0.269
T-BIL (mg/dL) 0.9 ± 0.5 0.7 ± 0.4 0.9 ± 0.4 0.7 ± 0.4 0.757 0.362 0.398
Crea (mg/dL) 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.807 0.033 0.470
UA (mg/dL) 6.1 ± 0.9 6.2 ± 1.2 5.9 ± 1.0 6.0 ± 1.2 0.212 0.069 0.370
UN (mg/dL) 154 ± 4.4 15.2 ± 3.9 16.1 ± 2.9 16.1 ± 2.3 0.986 0.165 0.366
AST (IU/L) 25.6 ± 5.8 24.1 ± 5.0 22.2 ± 4.4 22.5 ± 5.3 0.045 0.236 0.167
ALT (IU/L) 20.4 ± 9.7 21.8 ± 9.6 19.6 ± 8.8 26.3 ± 13.5 0.783 0.003 0.063
LDH (IU/L) 224.5 ± 30.6 192.8 ± 28.0 217.2 ± 45.7 187.1 ± 30.4 0.187 0.523 0.338
PLT (×1000/μL) 245.8 ± 48.6 250.4 ± 50.4 246.2 ± 29.7 251.9 ± 35.7 0.508 0.010 0.225
γ-GTP (IU/L) 20.4 ± 8.1 20.5 ± 5.3 19.8 ± 6.3 23.0 ± 6.8 0.966 0.019 0.092
Data are mean ± SD; p < 0.05 is considered significant (indicated in bold)
RBC red blood cell, WBC white blood cell, Hb hemoglobin, Ht hematocrit, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, MCHC mean
corpuscular hemoglobin concentration, T-BIL total bilirubin, Crea creatinine, UA uric acid, UN urea nitrogen, AST aspartate transaminase, ALT alanine transaminase,
LDH lactate dehydrogenase, PLT platelets, γ-GTP γ-glutamyl transpeptidase
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suggesting that EMIQ supplementation improves the
antioxidant status of players. To the best of our know-
ledge, this is the first report to show that antioxidants
increase lower limb muscle mass, suppressing antioxi-
dant stress.
During the experiments, body mass of players
remained unchanged. Lower limb lean masses of both
groups significantly increased between baseline and 4
months, possibly because of the training, a finding that
is consistent with that of a previous report [28]. Lower
limb muscle mass of participants in the EW group sig-
nificantly increased from baseline to 4 months, whereas
that of participants in the W group did not change sig-
nificantly. Increases in lower limb lean mass and muscle
mass were higher than in the EW group than in the W
group. These results suggest that EMIQ supplementa-
tion may optimize the exercise effect and intensifies
muscle hypertrophy in humans as they did in mice [11].
To clarify the detail mechanism of muscle hypertrophy
due to EMIQ, further investigations will be needed.
One of the speculative mechanisms is suppression of
oxidative stress. Antioxidant supplementation after exer-
cise affects inflammatory markers, muscle fatigue and
performance [29–31], although no report has suggested
that antioxidant supplementation intensifies muscle
hypertrophy. EMIQ supplementation may increase the
endurance or work capacity of players, as revealed by
studies that reported that quercetin improves muscle
Fig. 3 Lean body mass (a), fat mass (b), lower limb fat-free mass (c), lower limb muscle mass (d), and lower limb fat mass (e). Participants
consumed 20 g of their supplementary protein powder after exercise (6 days a week). Changes of body composition from 0 to 4 months were
expressed as mean change ±95% CI, and changes completely above or below the baseline are significant changes. *p < 0.05, significant
difference between W group and EW group
Table 5 Basic information
W group (n = 20) EW group (n = 19)
Mean ± SD Mean ± SD p value
Age (year) 19.7 ± 1.3 20.0 ± 1.5 0.440
Body height (cm) 173.7 ± 6.2 174.6 ± 5.8 0.631
Data are mean ± SD; BW body weighta
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damage or endurance exercise capacity [32, 33]. How-
ever, we could not measure endurance or work capacity
in this long-term study. Antioxidant status of a player is
related to performance during fatiguing exercise [34, 35];
therefore, improvement of antioxidant status by EMIQ
supplementation may be an advantage to players.
Another possible mechanism is the previously reported
function of quercetin as an activator of mitochondria bio-
genesis and PGC-1α [36, 37]; these functions may affect
muscle synthesis or breakdown [38, 39]. However, it is un-
certain that the effect on atrophy and muscular dystrophy
can be extrapolated to this small study [40]. In this study,
EMIQ was consumed with supplementary protein powder,
which may affect protein absorption and metabolism.
We observed no increases in the body weights in
either group. As mentioned before, participants under-
went training regularly and typically consumed
supplementary protein powder. Therefore, it is possible
that we did not observe significant increases in body
weight and body lean mass during this period, in accord-
ance with a previous study [41]. Meanwhile, some blood
parameters mainly those related to inflammation and
anemia, increased during the study, possibley because of
the strenuous training. d-ROMs also increased during
the study. These data indicate that during the study, all
participants were under strenuous exercise and stress,
with no differences between the groups.
In this study, we confirmed the safety of EMIQ. EMIQ
is generally regarded as safe (GRAS) by the US Food and
Drug Administration [7], and is approved as a food addi-
tive in Japan [6]. No adverse events were associated with
EMIQ supplementation during the study period. Blood
parameters did not alter with EMIQ supplementation,
indicating that 42 mg of EMIQ supplementation is safe.
Table 6 Body composition data from baseline to 4 month
Group Baseline 4 months p value
Mean ± SD Mean ± SD Time Group×Time
Body weight (kg) W group 76.1 ± 10.2 75.6 ± 11.1 0.743 0.150
EW group 74.9 ± 11.5 75.6 ± 12.1
BMI (kg/m2) W group 25.2 ± 2.6 25.0 ± 2.8 0.787 0.126
EW group 24.5 ± 2.8 24.7 ± 3.0
Lean body mass (kg) W group 62.8 ± 7.5 62.4 ± 7.8 0.427 0.645
EW group 61.7 ± 7.1 61.6 ± 7.3
FAT mass (kg) W group 11.2 ± 4.0 11.2 ± 4.3 0.108 0.101
EW group 11.5 ± 4.9 12.1 ± 5.1
Lower limb fat-free mass (g) W group 22,710.0 ± 2854.4 23,034.0 ± 2993.4 0.000 0.030
EW group 21,751.4 ± 2915.6 22,701.6 ± 3107.7
Lower limb muscle mass (g) W group 21,608.5 ± 2708.3 21,864.2 ± 2862.7 0.000 0.020
EW group 20,635.9 ± 2811.6 21,566.7 ± 3005.3
Lower limb fat mass (g) W group 4368.8 ± 1751.9 4430.7 ± 1798.0 0.013 0.078
EW group 4349.7 ± 1902.8 4692.0 ± 1998.7
Data are mean ± SD; p < 0.05 is considered significant (indicated in bold)
Table 7
Group Baseline 4 months p value
Mean ± SD Mean ± SD Time Group×Time
BAP (mmol/L) W group 2068.6 ± 228.3 2027.1 ± 173.7 0.406 0.938
EW group 2115.5 ± 340.1 2081.1 ± 208.0
d-ROMs (U.CARR) W group 249.1 ± 50.9 233.5 ± 34.7 0.016 0.884
EW group 230.5 ± 57.2 213.1 ± 50.5
BAP/d-ROMs W group 8.7 ± 2.5 8.8 ± 1.1 0.230 0.328
EW group 9.6 ± 2.4 10.3 ± 2.8*
Data are mean ± SD; p < 0.05 is considered significant (indicated in bold)
* p < 0.05, significant difference between the W group and the EW group
U.CARR (Carratelli Units), where 1 U.CARR corresponds to 0.08 mg/dL hydrogen peroxide
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Results of blood parameters revealed no health concerns
in the study participants.
Limitations
The present study evaluated only young male athletes
because participants included were American football
players of the university. Thus, there is a risk of age-re-
lated bias as age can be a factor affecting muscle hyper-
trophy. Furthermore, it remains unclear whether these
results can be observed in individuals who exercise less
frequently because exercise habits are also a factor. Fur-
ther studies on other participants based on these limita-
tions may clarify the effectiveness of EMIQ.
Conclusions
Our findings suggest that EMIQ exerts antioxidant ef-
fects, improving lower limb muscle mass in American
football players.
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